Cargando…
Adverse outcome associated with daratumumab-based treatments in relapsed/refractory multiple myeloma patients with amplification of chromosome arm 1q21: a single-center retrospective experience
Autores principales: | Barbieri, Emiliano, Maccaferri, Monica, Leonardi, Giovanna, Giacobbi, Francesca, Corradini, Giorgia, Lagreca, Ivana, Barozzi, Patrizia, Potenza, Leonardo, Marasca, Roberto, Luppi, Mario |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9646578/ https://www.ncbi.nlm.nih.gov/pubmed/36104630 http://dx.doi.org/10.1007/s00277-022-04978-6 |
Ejemplares similares
-
Selinexor, daratumumab, and dexamethasone in patients with relapsed or refractory multiple myeloma
por: Gasparetto, Cristina, et al.
Publicado: (2020) -
The Role of T Cell Immunity in Monoclonal Gammopathy and Multiple Myeloma: From Immunopathogenesis to Novel Therapeutic Approaches
por: Lagreca, Ivana, et al.
Publicado: (2022) -
Efficacy and Safety of Daratumumab, Pomalidomide, and Dexamethasone (DPd) Compared to Daratumumab, Bortezomib, and Dexamethasone (DVd) in Daratumumab–Naïve Relapsed Multiple Myeloma
por: Afrough, Aimaz, et al.
Publicado: (2023) -
Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment
por: Siegel, David S., et al.
Publicado: (2020) -
Role of Daratumumab in Combination With Standard Therapies in Patients With Relapsed and Refractory Multiple Myeloma
por: Bapatla, Anusha, et al.
Publicado: (2021)